½Ã°£ |
¹øÈ£ |
¼º¸í |
¼Ò¼Ó |
Á¦¸ñ |
ÁÂÀå : ¹é¿ø¿µ(°æ»óÀÇ´ë) |
12:30~13:10 |
GO1 |
ÁÖ¿õ |
ÀÌÈÀÇ´ë |
TP 53 restoration using E6/E7 siRNA potentiates therapeutic effect of cisplatin in cervical squamous cell carcinoma |
GO2 |
À̼ºÁ¾ |
°¡Å縯ÀÇ´ë |
Distribution of human papillomavirus type 58 variants in progression of cervical dysplasia in Korean women |
GO3 |
Àü½Ã¿ø |
ÀÌÈÀÇ´ë |
The association between MCP-1 and CCR2 single nucleotide polymorphisms and cervical intraepithelial neoplasia and cervical cancer in Korean women |
GO4 |
Á¶ÇѺ° |
¿¬¼¼ÀÇ´ë |
Multiplication of neutrophil and monocyte counts (MNM) as an easily obtainable tumor marker for cervical neoplasia |
ÁÂÀå : ÇãÁØ¿ë(°í·ÁÀÇ´ë) |
13:10~13:50 |
GO5 |
ÀÌ´ë¿ì |
¿¬¼¼ÀÇ´ë |
Clinical significance of tumor volume and lymph node involvement assessed by MRI in cervical cancer patients treated with concurrent chemotherapy and radiotherapy |
GO6 |
ÀÌÀ¯¿µ |
¼º±Õ°üÀÇ´ë |
The role of the maximal standardized uptake value (SUVmax) in positron emission tomography (PET) in early cervical cancer |
GO7 |
±èÀ±È¯ |
¼¿ïÀÇ´ë |
Adjuvant concurrent chemoradiotherapy-induced neutropenia as a prognostic factor in high-risk cervical cancer |
GO8 |
±èÈñ½Â |
¼¿ïÀÇ´ë |
Matched-case comparison for the role of surgery in FIGO stage Ib1-IIa squamous cell carcinoma of cervix and suspicious para-aortic lymph node metastasis |
ÁÂÀå : ¿À¼ºÅÃ(Àü³²ÀÇ´ë) |
13:50~14:30 |
GO9 |
°Èñ¼® |
¼º±Õ°üÀÇ´ë |
Relative high dose topotecan combined with carboplatin in recurrent epithelial ovarian cancer (EOC) |
GO10 |
±è¼öÇö |
Æ÷õÁß¹®ÀÇ´ë |
Gemcitabine-carboplatin-paclitaxel combination as first-line chemotherapy in advanced ovarian cancer |
GO11 |
À̼ºÇÏ |
°¡Å縯ÀÇ´ë |
Serial pattern of CA125 levels as a predictive value of recurrence in advanced epithelial ovarian cancer |
GO12 |
±è¹Ì°æ |
¼¿ïÀÇ´ë |
Neoadjuvant chemotherapy for stage III or IV ovarian cancer : Effects on optimal debulking rates and survival |
14:30~15:00 |
|
Coffee Break |
ÁÂÀå : ±èÀåÈí(°¡Å縯ÀÇ´ë) |
15:00~15:40 |
GO13 |
¹ÚÁ¤¿ |
¿ï»êÀÇ´ë |
Comparison of laparoscopic radical hysterectomy and abdominal radical hysterectomy for stage IA2-IIA cervical cancer: A matched case-control study |
GO14 |
À±Á¾¼÷ |
°¡Å縯ÀÇ´ë |
Neoadjuvant cisplatin and etoposide followed by radical hysterectomy for stage 1B-2B cervical cancer |
GO15 |
¹ÚÁø¿µ |
¾ÆÁÖÀÇ´ë |
Are the adjuvant chemoradiation using 3 ~ 4 cycles of 5-FU/Cisplatin adequate enough for all cervical cancer patients with high risk for treatment failure after radical hysterectomy? |
GO16 |
°¿ì´ë |
Àü³²ÀÇ´ë |
A clinical analysis of abnormal cervical cancer screening in private clinics |
ÁÂÀå : ·ùöÈñ(ÀüºÏÀÇ´ë) |
15:40~16:20 |
GO17 |
±è±âÇü |
ºÎ»êÀÇ´ë |
AZD6244 (ARRY-142886), a Potent MEK 1/2 Inhibitor, induces Selective Growth inhibition in Epithelial Ovarian cancer cells |
GO18 |
À̼±ÁÖ |
°Ç±¹ÀÇ´ë |
Combined effect of protein kinase B inhibitor or extracellular signal-regulated kinase inhibitor against farnesyltransferase inhibition-induced apoptosis in SiHa cells |
GO19 |
Àü¼· |
¼øõÇâÀÇ´ë |
Promoter methylation of runx3 gene in endometrial cancer |
GO20 |
½Å¼ÒÁø |
°è¸íÀÇ´ë |
Enhanced expression of transcription factor Nrf2 by isoliquiritigenin (ISL) in uterine leiomyoma cells. |
ÁÂÀå : ±è¼®Çö(¼¿ïÀÇ´ë) |
16:20~17:00 |
GO21 |
ÇÑÈ£¼· |
°üµ¿ÀÇ´ë |
Laparoscopic-assisted vaginal hysterectomy vs. abdominal hysterectomy in endometrial cancer |
GO22 |
Àü¿µÀº |
¿¬¼¼ÀÇ´ë |
Leukocyte differential count as a diagnostic and prognostic factor in endometrial cancer |
GO23 |
±è¹ÎÁ¤ |
¼¿ïÀÇ´ë |
What do Korean breast cancer patients need for sexual activity? |
GO24 |
±â°æµµ |
°æÈñÀÇ´ë |
Pulmonary toxicity after a quick course of combinatorial vincristine, bleomycin, and cisplatin neoadjuvant chemotherapy in cervical cancer |